Blunt Business
Dispensing Cannabis business knowledge beyond a million square feet of cultivation space. Blunt Business will navigate the challenges and opportunities of one of the most profitable industries on earth. Join us each episode to hear our weekly round tables and interviews with industry professionals.
10
Retail Innovations and Local Access Roll Out for New Cannabis Customers
<p>As the legal cannabis sector eagerly awaits federal reclassification judgments, industry players are aggressively pivoting toward untapped markets and hesitant, first-time consumers. In California, dispensaries are tearing down old retail friction points by introducing state-approved self-checkout kiosks equipped with multi-product RFID scanners, mimicking the familiarity and efficiency of traditional supermarket shopping. </p><p>Simultaneously, New York is expanding access points into everyday public life by enacting legislation that allows small cannabis businesses to sell directly at local farmers' markets. </p><p>By combining friction-free retail automation with accessible, community-based storefronts, the industry is reshaping its sales funnel to court a...
Beyond the Hearings: Navigating Cannabis's Legal Crossroads
<p>Although the historic DEA rescheduling hearings have officially concluded, the administrative process has ended without an immediate, final ruling, leaving the federal status of cannabis temporarily in limbo. </p><p>Despite the lack of a definitive outcome, the hearings marked a monumental breakdown in federal policy: medical cannabis operators are emerging as clear near-term winners due to the immediate relief from Section 280E tax burdens and expedited DEA registration opportunities, while the broader adult-use sector remains caught between federal delays and potential legal challenges. </p><p>Operators are now urged to take swift, strategic action—from restructuring tax methodologies to...
Navigating the DEA’s Cannabis Rescheduling Shift
<p>As the DEA moves toward rescheduling cannabis, the industry is bracing for a complex transformation defined by regulatory uncertainty and potential legal headwinds. While federal agencies have taken an unexpectedly active role in supporting this transition, the timeline for full implementation remains long and subject to likely legal challenges. Blunt Business speaks with Chris Lynch, partner at Dickinson Wright to chime in. </p><p>For businesses, the landscape is currently defined by heavy operational burdens, such as state-specific excise taxes and residency requirements; however, upcoming shifts like Section 280E relief and the prospect of federal trademark protection signal a...
Future of Cannabusiness: Brand Strategy and Industry Consolidation
<p>Joe Bayern with MM Brands outlines a strategic roadmap for professionalizing the cannabis industry, emphasizing that sustainable growth requires moving beyond fragmented operations. </p><p>Key strategies include adopting a portfolio-based management model to share operational and manufacturing costs, implementing minimalist, needs-based branding to simplify the consumer experience, and navigating regulatory hurdles through omnichannel agility. </p><p>Furthermore, Bayern advocates for a "one plant" regulatory framework and anticipates continued industry consolidation, noting that businesses must modernize their supply chains to drive the quality, consistency, and therapeutic reliability essential for long-term mainstream adoption.</p><br/><br/>Advertising Inquiries: https://redcircle...
The Ongoing Federal Rescheduling and Operational Hurdles in Cannabis
<p>Blunt Business welcomes Joe Bayern, the CEO of MM Brands to discuss how the cannabis industry is approaching a potential turning point as DOJ and DEA hearings conclude this July, with anticipation high for a move to Schedule 3 classification. </p><p>This reclassification could eliminate 280E tax constraints, driving better profitability, while FDA validation of therapeutic benefits promises to reduce stigma and build consumer trust. </p><p>Despite this momentum, the sector faces significant headwinds, specifically a critical shortage of experienced middle management and the ongoing difficulty of maintaining quality control and compliance amidst fragmented, state-specific regulations.</p><br/><...
Banking, Compliance, and the DOJ Hearing for Cannabis Rescheduling
<p>Once again we welcome back Nick Richards, Partner and co-chair of the cannabis law practice group at Greenspoon Marder about how the cannabis and hemp industries currently face a complex landscape defined by existential regulatory threats and critical federal proceedings. Financial institutions are increasingly wary, with potential hemp reclassification jeopardizing banking access and subjecting businesses to high-risk compliance hurdles.</p><p>Meanwhile, industry experts are closely monitoring the upcoming DOJ administrative hearings, which represent a pivotal, though non-binding, opportunity to challenge Schedule I status for cannabis. Despite concerns over limited transparency and the exclusion of key industry advocacy groups...
Courts, Cannabis, and Compliance: WNBA Policy Shifts vs. Impending Hemp Regulations
<p>The sports industry is witnessing a landmark normalization of cannabis, highlighted by the WNBA’s recent collective bargaining agreement which removed cannabis from its prohibited substances list in favor of supportive substance abuse treatment programs. While this signals a new era for athlete endorsements and professional branding, the broader cannabis and hemp sector faces a precarious future. Blunt Business speaks with Nick Richards, Partner and co-chair of the cannabis law practice group at Greenspoon Marder.</p><p>Businesses are currently bracing for a November 12th federal deadline that could redefine “illegal hemp,” potentially outlawing 95% of current CBD products and creati...
DOJ Rescheduling Preview | Virginia Amending Adult Use | Illinois Introduces Hemp Ban?
<p>We report on a wave of highly targeted legislative, legal, and medical updates aimed at curbing market disorder and protecting public health.</p><p>In the United States, Virginia has advanced a budget deal to its governor establishing a definitive July 2027 timeline for adult-use dispensary sales, while Illinois has enacted precise safety guardrails by banning intoxicating hemp sales to minors and enforcing strict child-proof packaging. This regulatory tightening faces immediate constitutional hurdles in the courts, where Ninth Circuit judges are currently deadlocked over whether sweeping state bans on cannabis billboard advertisements violate free speech.</p><p>Meanwhile, international markets...
Clarifying Cannabis From THCA Loopholes to Schedule III Shifts
<p>Dr. Priyanka Sharma, co-CEO of Kazmira Therapeutics and fellow co-CEO Pulak Sharma, cut through the confusion surrounding the rapidly evolving cannabis and hemp sectors. She clarifies the critical distinction between THCA—the non-intoxicating precursor that converts to THC upon heating—and delta-9 THC, noting that current marketing often masks the potential intoxicating effects of heated THCA products. </p><p>Dr. Sharma also unpacks the implications of the Schedule III reclassification, explaining why it creates a distinct "two-lane system" for medical cannabis versus industrial hemp rather than a blanket regulatory change.</p><br/><br/>Advertising Inquiries: https://redcircle.com/brands<br/>...
Kazmira Therapeutics and the Future of CBD Medicine
<p>Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations. </p><p>This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the mark...
